Puma Biotechnology Inc
PBYI5.830USD
+0.200+3.55%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
293.74MMarket Cap
7.77P/E TTM
More Details of Puma Biotechnology Inc Company
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company has in-licensed and is responsible for the global development and commercialization of alisertib. It intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.
Puma Biotechnology Inc Info
Ticker SymbolPBYI
Company namePuma Biotechnology Inc
IPO dateMar 21, 2012
CEOAuerbach (Alan H)
Number of employees172
Security typeOrdinary Share
Fiscal year-endMar 21
Address10880 Wilshire Blvd.
CityLOS ANGELES
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code90024
Phone14242486500
Websitehttps://www.pumabiotechnology.com/
Ticker SymbolPBYI
IPO dateMar 21, 2012
CEOAuerbach (Alan H)
Company Executives of Puma Biotechnology Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Alan H. Auerbach
Mr. Alan H. Auerbach
Chairman of the Board, President, Chief Executive Officer, Secretary
Chairman of the Board, President, Chief Executive Officer, Secretary
6.90M
-0.68%
Mr. Brian M. Stuglik
Mr. Brian M. Stuglik
Independent Director
Independent Director
94.96K
+24.85%
Ms. Allison Dorval, CPA
Ms. Allison Dorval, CPA
Independent Director
Independent Director
75.39K
+25.65%
Mr. Jay M. Moyes, CPA
Mr. Jay M. Moyes, CPA
Lead Independent Director
Lead Independent Director
53.32K
+10.35%
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
41.85K
-39.22%
Dr. Adrian M. Senderowicz, M.D.
Dr. Adrian M. Senderowicz, M.D.
Independent Director
Independent Director
27.00K
--
Dr. Troy E. Wilson, J.D., Ph.D.
Dr. Troy E. Wilson, J.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Douglas Hunt
Mr. Douglas Hunt
Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance, and Law Officer
Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance, and Law Officer
--
--
Mr. Michael P. (Mike) Miller
Mr. Michael P. (Mike) Miller
Independent Director
Independent Director
--
--
Mr. Mariann Ohanesian
Mr. Mariann Ohanesian
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Alan H. Auerbach
Mr. Alan H. Auerbach
Chairman of the Board, President, Chief Executive Officer, Secretary
Chairman of the Board, President, Chief Executive Officer, Secretary
6.90M
-0.68%
Mr. Brian M. Stuglik
Mr. Brian M. Stuglik
Independent Director
Independent Director
94.96K
+24.85%
Ms. Allison Dorval, CPA
Ms. Allison Dorval, CPA
Independent Director
Independent Director
75.39K
+25.65%
Mr. Jay M. Moyes, CPA
Mr. Jay M. Moyes, CPA
Lead Independent Director
Lead Independent Director
53.32K
+10.35%
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
41.85K
-39.22%
Dr. Adrian M. Senderowicz, M.D.
Dr. Adrian M. Senderowicz, M.D.
Independent Director
Independent Director
27.00K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Auerbach (Alan H)
13.69%
Acorn Capital Advisors, LLC
8.20%
The Vanguard Group, Inc.
7.33%
BlackRock Institutional Trust Company, N.A.
5.81%
Renaissance Technologies LLC
4.27%
Other
60.71%
Shareholders
Shareholders
Proportion
Auerbach (Alan H)
13.69%
Acorn Capital Advisors, LLC
8.20%
The Vanguard Group, Inc.
7.33%
BlackRock Institutional Trust Company, N.A.
5.81%
Renaissance Technologies LLC
4.27%
Other
60.71%
Shareholder Types
Shareholders
Proportion
Investment Advisor
39.71%
Investment Advisor/Hedge Fund
23.77%
Individual Investor
15.23%
Hedge Fund
6.51%
Research Firm
0.87%
Pension Fund
0.37%
Bank and Trust
0.10%
Venture Capital
0.05%
Family Office
0.02%
Other
13.36%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
253
35.42M
70.29%
-7.56M
2025Q2
253
40.80M
82.17%
-7.54M
2025Q1
256
39.74M
80.10%
-6.90M
2024Q4
254
38.30M
77.36%
-8.34M
2024Q3
246
40.62M
82.78%
-5.24M
2024Q2
238
41.70M
86.51%
-237.42K
2024Q1
243
40.11M
83.30%
-422.18K
2023Q4
241
36.65M
77.08%
-4.19M
2023Q3
280
35.58M
74.91%
-9.53M
2023Q2
294
33.81M
72.39%
-18.15M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Auerbach (Alan H)
6.90M
13.7%
-47.17K
-0.68%
Jul 09, 2025
Acorn Capital Advisors, LLC
4.13M
8.2%
+191.25K
+4.85%
Jun 30, 2025
The Vanguard Group, Inc.
3.71M
7.36%
+37.19K
+1.01%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.00M
5.96%
-4.07K
-0.14%
Jun 30, 2025
Renaissance Technologies LLC
1.87M
3.72%
+45.50K
+2.49%
Jun 30, 2025
Acadian Asset Management LLC
2.01M
3.99%
--
--
Jun 30, 2025
American Century Investment Management, Inc.
1.34M
2.66%
+192.62K
+16.75%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.15M
2.28%
+261.38K
+29.41%
Jun 30, 2025
Athyrium Capital Management, LP
1.26M
2.49%
--
--
Sep 30, 2024
Geode Capital Management, L.L.C.
971.67K
1.93%
+16.22K
+1.70%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Royce Quant Small-Cap Quality Value ETF
0.32%
First Trust Dow Jones Select MicroCap Index Fund
0.3%
Lattice Hartford Multifactor Small Cap ETF
0.24%
WisdomTree US SmallCap Fund
0.06%
Avantis US Small Cap Value ETF
0.04%
iShares Micro-Cap ETF
0.04%
Fidelity Enhanced Small Cap ETF
0.03%
Avantis US Small Cap Equity ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
Franklin US Small Cap Multifactor Index ETF
0.03%
View more
Royce Quant Small-Cap Quality Value ETF
Proportion0.32%
First Trust Dow Jones Select MicroCap Index Fund
Proportion0.3%
Lattice Hartford Multifactor Small Cap ETF
Proportion0.24%
WisdomTree US SmallCap Fund
Proportion0.06%
Avantis US Small Cap Value ETF
Proportion0.04%
iShares Micro-Cap ETF
Proportion0.04%
Fidelity Enhanced Small Cap ETF
Proportion0.03%
Avantis US Small Cap Equity ETF
Proportion0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.03%
Franklin US Small Cap Multifactor Index ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Puma Biotechnology Inc?
The top five shareholders of Puma Biotechnology Inc are:
Auerbach (Alan H) holds 6.90M shares, accounting for 13.70% of the total shares.
Acorn Capital Advisors, LLC holds 4.13M shares, accounting for 8.20% of the total shares.
The Vanguard Group, Inc. holds 3.71M shares, accounting for 7.36% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.00M shares, accounting for 5.96% of the total shares.
Renaissance Technologies LLC holds 1.87M shares, accounting for 3.72% of the total shares.
Auerbach (Alan H) holds 6.90M shares, accounting for 13.70% of the total shares.
Acorn Capital Advisors, LLC holds 4.13M shares, accounting for 8.20% of the total shares.
The Vanguard Group, Inc. holds 3.71M shares, accounting for 7.36% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.00M shares, accounting for 5.96% of the total shares.
Renaissance Technologies LLC holds 1.87M shares, accounting for 3.72% of the total shares.
What are the top three shareholder types of Puma Biotechnology Inc?
The top three shareholder types of Puma Biotechnology Inc are:
Auerbach (Alan H)
Acorn Capital Advisors, LLC
The Vanguard Group, Inc.
Auerbach (Alan H)
Acorn Capital Advisors, LLC
The Vanguard Group, Inc.
How many institutions hold shares of Puma Biotechnology Inc (PBYI)?
As of 2025Q3, 253 institutions hold shares of Puma Biotechnology Inc, with a combined market value of approximately 35.42M, accounting for 70.29% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -11.88%.
What is the biggest source of revenue for Puma Biotechnology Inc?
In --, the -- business generated the highest revenue for Puma Biotechnology Inc, amounting to -- and accounting for --% of total revenue.
